Study of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine) in CAP published in NEJM- Pfizer

Pfizer has announced the publication of findings from its Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) in the March 19 issue of The New England Journal of Medicine. The study investigated the efficacy of immunization with Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) to prevent a first episode of vaccine-type pneumococcal community-acquired pneumonia (CAP), including non-bacteremic/non-invasive CAP, and vaccine-type invasive pneumococcal disease (IPD) in adults aged 65 years and older.

The study achieved its primary and secondary objectives. For the primary endpoint, there were 45.6 percent fewer first episodes of vaccine-type CAP among Prevenar 13-vaccinated subjects than in subjects who received placebo (P<0.001). Regarding the study’s secondary endpoints, the Prevenar 13 group experienced 45.0 percent fewer first episodes of non-bacteremic/non-invasive vaccine-type CAP (P=0.007) and 75.0 percent fewer first episodes of vaccine-type IPD (P<0.001) compared with the placebo group. The safety profile of Prevenar 13 in this study was consistent with studies previously conducted in adults.